ClinicalTrials.Veeva

Menu

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

Allergan logo

Allergan

Status

Completed

Conditions

Macular Edema
Retinal Vein Occlusion

Treatments

Drug: Anti-VEGF

Study type

Observational

Funder types

Industry

Identifiers

NCT01918371
GMA-OZU-13-598

Details and patient eligibility

About

This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).

Enrollment

323 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Macular edema in the study eye due to RVO or DME
  • Received an anti-VEGF injection in the study eye on or after June 2010 for RVO and on or after August 2012 for DME

Exclusion criteria

  • None

Trial design

323 participants in 2 patient groups

Patients with RVO
Description:
Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
Treatment:
Drug: Anti-VEGF
Patients with DME
Description:
Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
Treatment:
Drug: Anti-VEGF

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems